Garcia Rosa, Badaró Roberto, Netto Eduardo M, Silva Marcio, Amorin Fabio S, Ramos Andre, Vaida Florin, Brites Carlos, Schooley Robert T
Federal University of Bahia, Brazil.
AIDS Res Hum Retroviruses. 2006 Dec;22(12):1248-52. doi: 10.1089/aid.2006.22.1248.
Antiretroviral therapy success is highly dependent on the ability of the patient to fully adhere to the prescribed treatment regimen. We present the results of a cross-sectional study that evaluates the predictive value of a self-administered questionnaire of adherence to antiretroviral (ARV) therapy. Study participants were interviewed using a 36-item Patient Medication Adherence Questionnaire (PMAQ) designed to assess knowledge about ARV therapy, motivation to adhere to treatment, and behavioral skills. Plasma HIV-1 RNA levels were correlated with the results obtained from the PMAQ. Of the 182 study participants, 82 (45%) were receiving their initial ARV regimen. Of the remaining patients, 39 (21%) and 61 (34%) were on a second or additional ARV regimen, respectively. An undetectable viral load was documented in 47/62 (76%) patients on their first regimen who reported missing medication on less than 4 days in the last 3 months. The PMAQ had a higher predictive value of plasma viral suppression for patients in the initial regimen than for patients in salvage therapy. The overall predictive value of the PMAQ to identify adherence was 74%, and 59% for nonadherence, with an overall efficacy of 64%. Of the 74 patients (45%) who did not understand the concept of antiretroviral therapy, 80% were failing or had previously failed the ARV treatment. Of 35 patients with doubts about their HIV status or skeptical of the benefits of ARV therapy, 29 (84%) were nonadherent. Despite the positive predictive value of PMAQ in identifying adherence, self-reported adherence is not a sufficiently precise predictor of treatment success to substitute for viral load monitoring. On the other hand, the use of such an instrument to identify factors associated with nonadherence provides an excellent opportunity to apply early intervention designed to specifically address factors that might be contributing to the lack of adherence prior to regimen failure.
抗逆转录病毒疗法的成功高度依赖于患者完全遵守规定治疗方案的能力。我们呈现了一项横断面研究的结果,该研究评估了一份自我管理的抗逆转录病毒(ARV)治疗依从性问卷的预测价值。使用一份36项的患者药物依从性问卷(PMAQ)对研究参与者进行访谈,该问卷旨在评估对抗逆转录病毒疗法的知识、坚持治疗的动机以及行为技能。血浆HIV-1 RNA水平与从PMAQ获得的结果相关。在182名研究参与者中,82名(45%)正在接受他们的初始抗逆转录病毒治疗方案。在其余患者中,39名(21%)和61名(34%)分别正在接受第二种或额外的抗逆转录病毒治疗方案。在62名接受第一种治疗方案且报告在过去3个月中漏服药物少于4天的患者中,有47名(76%)的病毒载量检测不到。对于初始治疗方案的患者,PMAQ对血浆病毒抑制的预测价值高于挽救治疗的患者。PMAQ识别依从性的总体预测价值为74%,识别不依从性的为59%,总体有效性为64%。在74名(45%)不理解抗逆转录病毒疗法概念的患者中,80%的患者治疗失败或之前曾治疗失败。在35名对自己的HIV状态有疑问或怀疑抗逆转录病毒疗法益处的患者中,29名(84%)不依从。尽管PMAQ在识别依从性方面具有阳性预测价值,但自我报告的依从性并不是治疗成功的足够精确的预测指标,无法替代病毒载量监测。另一方面,使用这样一种工具来识别与不依从相关的因素,为应用早期干预提供了绝佳机会,这种早期干预旨在专门解决在治疗方案失败之前可能导致不依从的因素。